IGC Pharma, Inc. IGC AMEX · Healthcare · United States
$0.20 -2.93% -$0.01
Summary
31 / 100 · Bulios Score
What speaks for it
- It has no debt and holds $377.0K in cash.
- The price moves less than the market (beta 0.49).
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 5.7% a year over 5 years. Over the last 3 years it grew by 9.2% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $8.11M.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Tolling White Labeling Service Member 91%
- WellnessAndLifestyleMember 8.9%
By region
- UNITED STATES 100%
- COLOMBIA 0.2%
Tolling White Labeling Service Member brings in 91% of revenue.
Segments in detail